Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer	HER2-positive Breast Cancer	Not yet recruiting	Not stated	2026-03-13		NCT07470203

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Peking University Cancer Hospital & Institute	189

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials